biologics

Biosimilars safety performance in psoriasisA study that compares the safety, efficacy and drug survival of biologics to biosimilars, finds that switching to a biosimilar had no significant impact on drug survival or safe
Moderate plaque psoriasis may resolve with apremilastWhile there are biologics and systemic agents designed to control the severe form of plaque psoriasis, few treatments work as well in moderate plaque psoriasis. Apremilast may be a game changer.
FDA approves a new, more powerful psoriasis drug“As we move toward finding a cure for psoriasis, what we are looking for are high performance drugs that provide durable response in between treatments and that lend themselves to patient compliance,” says Dr. George Martin.
Neurologic changes that stem from biologic therapyPhysicians should be aware of the warning signs that a biologic agent could be to blame when patients experience subacute or rapidly progressive neurologic changes, researchers say.
Dupilumab controls atopic dermatitis symptoms in patients with asthmaAdults with moderate to severe atopic dermatitis with comorbid asthma experience the same improvement in disease signs and symptoms with dupilumab treatment as those without asthma, according to pooled data from two large phase three clinical trials.
Laddered treatment for pityriasis rubra pilarisDiagnosing PRP is challenging because it can mimic eczema, psoriasis, or even ichthyosis. Biologic treatment for refractory cases considered, researchers said at AAD 2018.
Biologics offer promise for hidradenitis suppurativa treatmentWith one approved biologic available and many more under investigation, the future of treatment for hidradenitis suppurativa looks very promising.
Switching biologic treatments in dermatologyNot all biologic treatments are equal. Side effects, effectiveness, cost and administration style are among factors physicians should consider when switching treatments, experts report at AAD 2018.
The promise of biologic therapy in dermatologyDuring the American Academy of Dermatology’s annual meeting, physicians addressed the monumental changes that have occurred since the advent of biologic therapy for systemic autoimmune conditions, such as psoriasis and atopic dermatitis. Today, some patients are able to achieve complete disease clearance. Although there may be viable treatments for these conditions, access to care and medication adherence remain top issues, physicians say.
Three Barriers to Biosimilar AdoptionUnderstanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.